메뉴 건너뛰기




Volumn 11, Issue 4, 2004, Pages 329-332

Ciclopirox in the treatment of seborrhoeic dermatitis;Cyklopiroks w leczeniu łojotokowego zapalenia skóry

Author keywords

Ciclopirox; Seborrhoeic dermatitis

Indexed keywords

CICLOPIROX;

EID: 11244331527     PISSN: 1232986X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (5)

References (26)
  • 1
    • 11244353758 scopus 로고    scopus 로고
    • Łojotokowe zapalenie skóry - Powaźny problem dermatologiczny
    • Kołodziej T., Białynicki-Birula R.: Łojotokowe zapalenie skóry - powaźny problem dermatologiczny. Derm. Klin. Zabieg., 1999, 1, 95-98.
    • (1999) Derm. Klin. Zabieg. , vol.1 , pp. 95-98
    • Kołodziej, T.1    Białynicki-Birula, R.2
  • 2
    • 0026082144 scopus 로고
    • The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs
    • McGrath J., Murphy G.M.: The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. Drugs, 1991, 41, 178-184.
    • (1991) Drugs , vol.41 , pp. 178-184
    • McGrath, J.1    Murphy, G.M.2
  • 3
    • 0030753408 scopus 로고    scopus 로고
    • Dandruff and seborrhoeic dermatitis: Causes and management
    • Hay R.J., Graham-Brown R.A.: Dandruff and seborrhoeic dermatitis: causes and management. Clin. Exp. Dermatol., 1997, 22, 1-3.
    • (1997) Clin. Exp. Dermatol. , vol.22 , pp. 1-3
    • Hay, R.J.1    Graham-Brown, R.A.2
  • 4
    • 11244277470 scopus 로고    scopus 로고
    • Malassezia furfur: In vitro susceptibility against antifungal agents and production of reactive oxygen species
    • Reinl P., Nenoff P., Hipler U.C., Haustein U.F.: Malassezia furfur: In vitro susceptibility against antifungal agents and production of reactive oxygen species. Mycoses, 1999, 42, 153-154.
    • (1999) Mycoses , vol.42 , pp. 153-154
    • Reinl, P.1    Nenoff, P.2    Hipler, U.C.3    Haustein, U.F.4
  • 5
    • 0024997823 scopus 로고
    • Rilopirox: A new hydroxypyridone antifungal with fungicidal properties
    • Raether W., Hanel H.: Rilopirox: a new hydroxypyridone antifungal with fungicidal properties. Mycoses, 1990, 33, 191-202.
    • (1990) Mycoses , vol.33 , pp. 191-202
    • Raether, W.1    Hanel, H.2
  • 6
    • 0031456299 scopus 로고    scopus 로고
    • The hydroxypyridones: A class of antimycotics of its own
    • Karting H.C., Grundmann-Kollmann M.: The hydroxypyridones: a class of antimycotics of its own. Mycoses, 1997, 40, 243-247.
    • (1997) Mycoses , vol.40 , pp. 243-247
    • Karting, H.C.1    Grundmann-Kollmann, M.2
  • 7
    • 0017927884 scopus 로고
    • Mode of action of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pirydone etanolamine salt (Hoe 296)
    • Sakurai K., Sakaguchi T., Yamaguchi H., Iwata K.: Mode of action of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pirydone etanolamine salt (Hoe 296). Chemiotherapy, 1978, 24, 68-76.
    • (1978) Chemiotherapy , vol.24 , pp. 68-76
    • Sakurai, K.1    Sakaguchi, T.2    Yamaguchi, H.3    Iwata, K.4
  • 8
    • 0034855798 scopus 로고    scopus 로고
    • Ciclopirox: An overview
    • Gupta A.K.: Ciclopirox: An overview. Int. J. Dermatol., 2001, 40, 1-7.
    • (2001) Int. J. Dermatol. , vol.40 , pp. 1-7
    • Gupta, A.K.1
  • 9
    • 0023793684 scopus 로고
    • Comparison of ciclopirox olamine 1% cream with 1% hydrocortisone acetate cream in the treatment of inflamed superficial mycoses
    • Lassus A., Molting K.S., Savopoulos C.: Comparison of ciclopirox olamine 1% cream with 1% hydrocortisone acetate cream in the treatment of inflamed superficial mycoses. Clin. Ther., 1988, 10, 594-599.
    • (1988) Clin. Ther. , vol.10 , pp. 594-599
    • Lassus, A.1    Molting, K.S.2    Savopoulos, C.3
  • 10
    • 0030715379 scopus 로고    scopus 로고
    • Anti-inflammatory activity of antifungal preparations
    • Rosen T., Schell B.J., Orengo I.: Anti-inflammatory activity of antifungal preparations. Int. J. Dermatol., 1997, 36, 788-792.
    • (1997) Int. J. Dermatol. , vol.36 , pp. 788-792
    • Rosen, T.1    Schell, B.J.2    Orengo, I.3
  • 11
    • 0042413558 scopus 로고    scopus 로고
    • In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity
    • Gupta A.K., Kohli Y.: In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br. J. Dermatol., 2003, 2, 296-305.
    • (2003) Br. J. Dermatol. , vol.2 , pp. 296-305
    • Gupta, A.K.1    Kohli, Y.2
  • 12
    • 0025859326 scopus 로고
    • Ciclopirox cream 1%: In vitro and in vivo penetration into the stratum corneum
    • Caschin-Roques C.G., Hanel H., Pruja-Bougaret S.M.: Ciclopirox cream 1%: in vitro and in vivo penetration into the stratum corneum. Skin. Pharmacol., 1991, 4, 95-99.
    • (1991) Skin. Pharmacol. , vol.4 , pp. 95-99
    • Caschin-Roques, C.G.1    Hanel, H.2    Pruja-Bougaret, S.M.3
  • 14
    • 0024155777 scopus 로고
    • Evaluation of fungicidal action in vitro and in a skin model considering the influence of penetration kinetics of various standard antimycotics
    • Hanel H., Raether W., Dittmar W.: Evaluation of fungicidal action in vitro and in a skin model considering the influence of penetration kinetics of various standard antimycotics. Ann. N.Y. Acad. Sci., 1988, 544, 329-337.
    • (1988) Ann. N.Y. Acad. Sci. , vol.544 , pp. 329-337
    • Hanel, H.1    Raether, W.2    Dittmar, W.3
  • 17
    • 0031456299 scopus 로고    scopus 로고
    • The hydroxypirydones: A class of anti mycotics of its own
    • Korting H.C., Grundmann-Kollmann M.: The hydroxypirydones: a class of anti mycotics of its own. Mycoses, 1997, 40, 243-247.
    • (1997) Mycoses , vol.40 , pp. 243-247
    • Korting, H.C.1    Grundmann-Kollmann, M.2
  • 18
    • 0035723903 scopus 로고    scopus 로고
    • Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopirxolamine 1% cream in facial seborrhoeic dermatitis
    • Dupuy P., Maurette C., Amoric J.C., Chosidow O.: Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopirxolamine 1% cream in facial seborrhoeic dermatitis. Br. J. Dermatol., 2001, 5, 1033-1037.
    • (2001) Br. J. Dermatol. , vol.5 , pp. 1033-1037
    • Dupuy, P.1    Maurette, C.2    Amoric, J.C.3    Chosidow, O.4
  • 19
    • 0036203489 scopus 로고    scopus 로고
    • Ciclopiroxolamine cream 1% in the treatment of seborrhoeic dermatitis: A double-blind, parallel-group comparison with ketokonazole and vehicle in a confirmatory trial
    • Unholzer A., Schinzel S., Nietsche K.-H., Jung G.E., Korting H.C.: Ciclopiroxolamine cream 1% in the treatment of seborrhoeic dermatitis: a double-blind, parallel-group comparison with ketokonazole and vehicle in a confirmatory trial. Clin. Drug. Invest., 2002, 22, 167-172.
    • (2002) Clin. Drug. Invest. , vol.22 , pp. 167-172
    • Unholzer, A.1    Schinzel, S.2    Nietsche, K.-H.3    Jung, G.E.4    Korting, H.C.5
  • 21
    • 0036082147 scopus 로고    scopus 로고
    • A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoons containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2% Nizoral) for the treatment of dandruff/seborrhoeic dermatitis
    • Squire R.A., Goode K.: A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoons containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2% Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J. Dermatol. Treat., 2002, 13, 51-60.
    • (2002) J. Dermatol. Treat. , vol.13 , pp. 51-60
    • Squire, R.A.1    Goode, K.2
  • 22
  • 23
    • 4344658524 scopus 로고    scopus 로고
    • Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: Results of a double-blind, vehicle-controlled trial
    • Lebwohl M., Plott T.: Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int. J. Dermatol., 2004, 43, Suppl. 1, 17-20.
    • (2004) Int. J. Dermatol. , vol.43 , Issue.SUPPL. , pp. 17-20
    • Lebwohl, M.1    Plott, T.2
  • 24
    • 4344714176 scopus 로고    scopus 로고
    • Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: Results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage
    • Abeck D., Loprox Shampoo Dosing Study Group: Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int. J. Dermatol., 2004, 43, Suppl. 1, 13-16.
    • (2004) Int. J. Dermatol. , vol.43 , Issue.SUPPL. , pp. 13-16
    • Abeck, D.1
  • 25
    • 4344661281 scopus 로고    scopus 로고
    • Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: Results of a randomized, double-blind, vehicle-controlled trial
    • Altmeyer P., Hoffmann K., Loprox Shampoo Dosing Concentration Study Group: Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial. Int. J. Dermatol., 2004, 43, Suppl. 1, 9-12.
    • (2004) Int. J. Dermatol. , vol.43 , Issue.SUPPL. , pp. 9-12
    • Altmeyer, P.1    Hoffmann, K.2
  • 26
    • 0037246385 scopus 로고    scopus 로고
    • Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrhoeic dermatitis
    • Chosidow O., Maurette C., Dupuy P.: Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrhoeic dermatitis. Dermatology, 2003, 3, 233-240.
    • (2003) Dermatology , vol.3 , pp. 233-240
    • Chosidow, O.1    Maurette, C.2    Dupuy, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.